Drug Profile


Alternative Names: PRL3-ZUMAB

Latest Information Update: 22 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator INTRA-IMMUSG
  • Developer INTRA-IMMUSG; National University Hospital (Singapore)
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Prolactin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 22 Jun 2017 Pharmacodynamics data from a preclinical trial in Solid tumours released by INTRA-IMMUSG
  • 20 Feb 2017 Phase-I clinical trials in Solid tumours (Metastatic disease, In adults, In the elderly, Late-stage disease, Inoperable/Unresectable) in Singapore (IV) (NCT03191682)
  • 16 Jun 2016 Preclinical trials in Solid tumours in Singapore (IV) before June 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top